Navigation Links
International Committee Recommends Stringent Guidelines for Translating Stem Cell Therapies From the Lab Bench to the Bedside
Date:6/12/2008

PHILADELPHIA, June 12 /PRNewswire-USNewswire/ -- The Internet is rife with provider Web sites and patient testimonials touting exciting new stem cell treatments for paralysis, Parkinson's disease, heart failure and cancer. And every year, desperately ill patients travel thousands of miles to seek experimental stem cell therapies with bold claims of cures for such intractable diseases.

Few, if any, of these putative treatments are based on sound pre-clinical data that have been published in peer-reviewed journals. Today, there are no proven treatments based on stem cells other than those for blood disorders, like leukemia and immune deficiencies. All other stem cell treatments are still highly experimental.

At the sixth annual meeting of the International Society for Stem Cell Research, a task force of leaders in the field announced a draft set of guidelines to ensure that rigorous best practices are applied to the clinical translation of stem cell research from the laboratory to human subjects. The guidelines are the culmination of months of discussion by scientists, ethicists, public policymakers, clinicians, industry representatives and members of the public from 13 countries. (The full guidelines will be posted at http://www.isscr.org.)

"These guidelines are critically important to the future success of the field," according to Dr. George Q. Daley, ISSCR president and associate director of the Stem Cell Program at Children's Hospital Boston. "Not only does the use of untested therapies put patients at risk, it jeopardizes the legitimate practice of all translational stem cell research."

In strongly worded language, the guidelines "condemn" the use of stem cell therapies outside of an established clinical trial, particularly when patients are charged for "advertised medical services that constitute experimental, unproven and unestablished interventions." The guidelines call upon re
'/>"/>

SOURCE International Society for Stem Cell Research
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Maternal malaria researcher wins prestigious international prize
2. DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France
3. 8th International Conference on Pain and Chemical Dependency
4. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
5. ATS Medical Products Prominently Featured in International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Scientific Presentations
6. HealthSTAR Public Relations Joins GlobalCom PR-Network of International Agencies
7. The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
8. International Esthetics, Cosmetics & Spa Conference - Las Vegas
9. 6 Nobel Prize Winners at International Congress of Genetics
10. Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
11. International Diabetes Federation Commits to Improving Diabetes Education Globally Through Centres of Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... four months of hormonal therapy before and with ... by as much as eight yearsespecially the development ... with potentially aggressive prostate cancer. This neoadjuvant hormonal ... developing bone metastases avoid long-term hormonal therapy later ...
... immune cells seems to halt the cells typical job ... study by Johns Hopkins researchers suggests. The findings ... ranging from annoying bouts of hay fever to deadly ... his colleagues at the Johns Hopkins Asthma and Allergy ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... 2008) Athanasios Zavras began receiving messages from distraught ... meds to bone death in the jaw. A number ... these drugs to postpone dental work, fearing that procedures ... when Zavras, an associate professor in the Harvard School ...
... (ACP) has received a Commonwealth Fund grant of nearly $225,000 ... The grant, part of the Commonwealth Funds Patient-Centered Primary ... in November. ACP committed matching funds late in 2007. ... goal is to put the needs of the patient first. ...
... use of opioid drugs to relieve severe pain, black ... to receive these pain-relievers in emergency rooms, according to ... for more than 150,000 pain-related visits to U.S. hospitals ... of whites received opioid drugs compared with only 23 ...
Cached Medicine News:Health News:Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years 2Health News:Protein a possible key to allergy and asthma control 2Health News:Protein a possible key to allergy and asthma control 3Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2Health News:American College of Physicians receives grant to study cost of patient-centered medical home 2Health News:Blacks, Hispanics less likely to get strong pain drugs in emergency rooms 2
(Date:10/1/2014)... ANDOVER, Mass. , Oct. 1, 2014 /PRNewswire/ ... ; AEX: PHIA) today announced its eCareCoordinator and ... the U.S. Food and Drug Administration (FDA). A ... of telehealth programs , eCareCoordinator and eCareCompanion are ... are the first clinical applications to be available ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
(Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
... Calif., Sept. 19, 2011 Amgen (NASDAQ: ... Drug Administration (FDA) approved two new indications for Prolia® ... women at high risk for fracture receiving adjuvant aromatase ... to increase bone mass in men at high risk ...
... Sept. 19, 2011 Boston Scientific Corporation (NYSE: ... a highly deliverable and ultra-low profile 0.014 inch balloon ... procedures below the knee.  The Company has begun marketing ... markets.   Boston Scientific developed the Coyote ...
Cached Medicine Technology:FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 2FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 3FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 4FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 5FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 6FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 7FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 8Boston Scientific Launches Coyote™ Balloon Catheter 2Boston Scientific Launches Coyote™ Balloon Catheter 3Boston Scientific Launches Coyote™ Balloon Catheter 4
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
Coronary angiographic catheter...
Leksell Neuro Generator is a complete system for stereotactic lesioning, pain treatment, stimulation and bipolar coagulation. It features a radio frequency (RF) energy source with sophisticated, inte...
Medicine Products: